Stryker Corporation (SYK) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extrem...
Stryker Corporation (SYK) currently trades at a P/E ratio of 30.31 (historical range: 27.75–55.89, median: 41.71), placing it at the 2th percentile — cheap relative to its history, P/S ratio of 4.37 (range: 4.00–7.02, 4th percentile — cheap relative to its history), EV/EBITDA of 22.59 (range: 19.93–47.02, 2th percentile).
Stryker Corporation trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 30.31 | 41.71 | 2th | cheap relative to its history |
| P/S Ratio | 4.37 | 5.82 | 4th | cheap relative to its history |
| EV/EBITDA | 22.59 | 37.34 | 2th | cheap relative to its history |
| FCF Yield | 4.16% | 2.45% | 98th | cheap relative to its history |
Stryker Corporation (SYK) Valuation & P/E History
Stryker Corporation (SYK) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $295.00 with a market capitalization of $113.2 billion. This page provides historical valuation analysis for SYK based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 30.31 is below the historical median of 41.71, placing SYK at the 2th percentile of its valuation range. The P/S ratio of 4.37 compares to a median of 5.82.
SYK Valuation Metrics & Historical Range
The valuation table above shows Stryker Corporation's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether SYK is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests SYK is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Stryker Corporation.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is SYK Overvalued or Undervalued?
Stryker Corporation trades well below its historical valuation range across most metrics. The overall valuation percentile of 3 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive SYK is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full SYK analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.SYK trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.